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ABSTRACT
Introduction: Stereotactic radiosurgery (SRS) is a promising treatment option for patients with mul-
tiple brain metastases (BM). Recent technical advances have made LINAC based SRS a patient friendly
technique, allowing for accurate patient positioning and a short treatment time. Since SRS is increas-
ingly being used for patients with multiple BM, it remains essential that SRS be performed with the
highest achievable quality in order to prevent unnecessary complications such as radionecrosis. The
purpose of this article is to provide guidance for high-quality LINAC based SRS for patients with BM,
with a focus on single isocenter non-coplanar volumetric modulated arc therapy (VMAT).
Methods: The article is based on a consensus statement by the study coordinators and medical physi-
cists of four trials which investigated whether patients with multiple BM are better palliated with SRS
instead of whole brain radiotherapy (WBRT): A European trial (NCT02353000), two American trials and
a Canadian CCTG lead intergroup trial (CE.7). This manuscript summarizes the quality assurance meas-
ures concerning imaging, planning and delivery.
Results: To optimize the treatment, the interval between the planning-MRI (gadolinium contrast-
enhanced, maximum slice thickness of 1.5mm) and treatment should be kept as short as possible
(< two weeks). The BM are contoured based on the planning-MRI, fused with the planning-CT. GTV-PTV
margins are minimized or even avoided when possible. To maximize efficiency, the preferable technique is
single isocenter (non-)coplanar VMAT, which delivers high doses to the target with maximal sparing of the
organs at risk. The use of flattening filter free photon beams ensures a lower peripheral dose and shortens
the treatment time. To bench mark SRS treatment plan quality, it is advisable to compare treatment plans
between hospitals.
Conclusion: This paper provides guidance for quality assurance and optimization of treatment delivery
for LINAC-based radiosurgery for patients with multiple BM.
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Introduction
Whole brain radiotherapy (WBRT) was traditionally the
cornerstone of treatment for patients with multiple brain
metastases (BM). WBRT has significant side effects, such as
hair loss, fatigue, and cognitive dysfunction which result in a
decreased quality of life (QOL) [1,2]. In the last decades,
stereotactic radiosurgery (SRS) has become the standard of
care for patients with a limited number of BM [3]. Recently,
SRS has become a treatment option in patients with 4 or
more BM. Yamamoto et al. found a similar overall survival for
patients with multiple BM (5–10) compared to limited BM
(2–4) when treated with SRS or fractionated stereotactic
radiotherapy in low volume BM [4]. For selected patients
with a single small brain metastasis, SRS may extend survival
and avoid invasive surgery, without compromising local con-
trol [5]. There are important advantages of SRS over WBRT,
i.e., limiting radiation to the uninvolved brain and obtaining
a high probability of local tumor control with a sin-
gle treatment.
Until recently, linear accelerator (LINAC) based radiosur-
gery has required each metastasis to be treated using a dis-
tinct isocenter, with the patient immobilized in an invasive
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frame. Recent technical advances have made LINAC based
SRS significantly more efficient and patient friendly. First of
all, cone-beam CT imaging has made it possible to detect
translational and rotational set-up errors.
Secondly, robotic couches have made it possible to cor-
rect rotational setup errors [6,7]. Combined with the use of
proper immobilization masks, this eliminates the need for
invasive frames [8]. SRS with immobilization masks and a six-
degrees-of-freedom (6-DOF) robotic couch under the guid-
ance of cone beam CT is a widely adopted treatment.
Translational and rotational errors can be corrected within
0.3–0.5mm and 0.3 when using cone beam CT and a 6-DOF
couch [9–11]. Another study shows that institutes with real-
time tracking capabilities and robotic couches are capable of
correcting rotational errors within 0.5 for most patients.
With a rotational error of 0.5 the coverage of the target is
still 95% and the risk of a compromised coverage increases
due to an increasing rotational error [12].
Thirdly, this improved patient positioning makes it pos-
sible to treat multiple BM with one isocenter. Most treatment
planning systems can be used to optimize a treatment plan
with one isocenter. There are some examples of commercial
systems which offer specific forms of automation for the pur-
pose of planning with one isocenter: HyperArcTM (HA)
(Varian Medical System, Palo Alto, CA), Monaco HDRS (Elekta
AB, Stockholm, Sweden) and MultipleBrainMetsTM (MBM)
(Brainlab AG, Munchen, Germany). Several studies analyzed
the plan quality of such techniques, with promising results
[13–16]. Ruggieri et al. compared the plan quality and dosi-
metric accuracy of MBM and HA. They concluded that both
techniques were able to generate high quality plans for
patients with multiple BM using SRS [15]. Furthermore, since
this a promising and safe treatment option for multiple BM
in a single treatment or fractionated treatment, this also has
the potential to have a positive impact on the costs of
SRS [17].
Lastly, the use of flattening filter free (FFF) beams have
further decreased the treatment time. The beam-on time
when treating three to twelve brain metastases has been
quantified before. It was found that three metastases could
be treated in approximately six minutes on a LINAC with FFF
and robotic couch, compared to 45–50minutes on a
GammaKnife. This time increased to nine minutes on the
LINAC to as much as 2.5 hours on a GammaKnife for twelve
metastases [18]. Depending on the chosen number of isocen-
ters and beam configurations, multiple BM can be treated
simultaneously within thirty minutes on a LINAC. The risk of
an intra-fraction positioning error (>3mm) is very small
when using immobilization masks and a robotic couch. A
retrospective study showed that a prolonged treatment time
is associated with a greater risk for treatment positioning
errors. Therefore, time delays between imaging and delivery
should be kept under five minutes to maintain a low risk for
positioning deviations. If longer time delays occur, one may
decide to verify the patient’s position again [19].
When using a non-coplanar LINAC technique, the con-
formity of the FFF based plans is comparable to GammaKnife
treatment plans [16,20]. A detailed analysis of factors
affecting LINAC non-coplanar plan quality revealed that low
dose spillage can be modulated during the treatment plan
optimization process [21].
Other factors that may affect clinical outcome of SRS are
the GTV-PTV margin that is used as well as the SRS prescrip-
tion dose. A randomized trial has shown that 1mm GTV-PTV
margin resulted in equal local control as 3mm GTV-PTV mar-
gin despite physical uncertainties [22]. An explanation for
the equal local control in both study arms is the dose pen-
umbra outside the PTV which also sterilizes microscopic dis-
ease. Using a 3mm GTV-PTV margin results in a higher
normal tissue complication probability of radionecrosis than
1mm GTV-PTV margin, due to high dose spillage in the nor-
mal brain tissue. Therefore the authors indicate that a 1mm
GTV-PTV margin would be ideal, but possible uncertainties
such as patient setup and accuracy, should be considered
when choosing the margin. To further lower the risk of radio-
necrosis, the dose prescription can be adapted. With a risk-
adapted approach, a high dose is prescribed for small BM
(single fraction of 21 or 24Gy) and a relatively low dose is
prescribed for large BM (e.g., single fraction of 15 or 18Gy or
3 fractions of 8 Gy). When using this approach in a BM larger
than 2 cm in diameter, a relatively high dose is spilled in the
normal brain tissue, resulting in an increased risk of radio-
necrosis as the V12Gy exceeds 10 cm3. Radiation-induced
brain necrosis in patients who are treated with SRS or multi-
fraction stereotactic radiotherapy for BM larger than 2 cm
has been investigated. It was concluded that multifraction
SRS (27 Gy in 3 fractions) is an effective treatment for large
BM and is associated with a reduced risk of radionecrosis,
compared to SRS [23]. A relatively new strategy to mitigate
the risk of radionecrosis is isotoxic dose prescription. With
this approach the tolerance level for radionecrosis is always
respected and the dose in the BM is adapted to respect the
tolerance level. Clinical studies are needed to validate the
promising in-silico results [24,25]. Mitigating the risk of radio-
necrosis is important to maintain SRS as a treatment option
for patients with BM in a multimodality approach.
After SRS, there is a relatively high risk of development of
new BM during follow-up, so called Distant Brain
Recurrences (DBR). One of the factors that correlates with
the risk of DBR development is the number of BM treated
initially with SRS, but volume of the initial treated BM, and
age play a role as well [26]. Level I evidence for the value
of SRS is already available for patients with a limited number
of BM, but needs to be determined in patients with four or
more BM [5]. Currently, WBRT or primary systemic treatments
are frequently being used in patients with four or more BM.
However, the outcome of WBRT is disappointing in the
setting of BM [27]. To investigate whether patients are better
palliated with SRS than with WBRT, several prospective phase
II/III trials are currently being initiated or ongoing: A
European trial (NCT02353000), two American trials, and a
Canadian CCTG lead intergroup trial (CE.7). The European
trial was closed after two years due to poor accrual
(NCT02353000) after randomizing 30 patients. Patients, refer-
ral physicians, and also some radiation oncologists prefer SRS
above WBRT in a multimodality approach in which systemic
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therapies are increasingly the cornerstone of the treatment.
It is important that SRS is performed with the highest pos-
sible quality in the different centers within and outside of
randomized trials. In each step of the process, the quality of
treatment from patient imaging to planning and delivery,
must be assured [28]. This work summarizes the quality
assurance measures with the goal to provide guidance for
high-quality LINAC based SRS for BM patients. The article is
based on a consensus statement of the study coordinators
and medical physicists of the four trials and other thought
leaders for quality assurance of SRS, with a special focus on
single isocenter non-coplanar volumetric modulated arc ther-
apy (VMAT).
Patient selection and endpoints in trials
In general, patients with BM are suitable for SRS if they have
a Karnofsky performance status of 70 or more, harbor BM
that have a maximum diameter of four cm, and have extrac-
ranial treatment options. From an anatomy perspective, BMs
need to be separated from the optic apparatus to avoid vis-
ual complications. In a large prospective cohort study
patients with two to four BM had equal survival as patients
with five to ten BM [4,29]. Not only patients with a single BM
had a more favorable prognosis, but also long term survivors
were observed in patients with five or more BM. In this
study, the maximum diameter of the largest BM was three
cm, the maximum volume of the largest BM was ten cm3
and the maximum total volume of the BM was fifteen cm3.
In the four initiated randomized trials there are small discrep-
ancies with respect to inclusion and exclusion criteria, also
with respect to SRS on brainstem metastases. All trial proto-
cols respect a maximum number and size of the BM (e.g.,
maximum diameter of 2.5 cm, a maximum cumulative vol-
ume of 30 cm3, and a maximum of ten or fifteen BM). These
inclusion criteria are consensus based, and not evidence
based, with a relation to toxicity, such as the risk of radio-
necrosis. Table 1 visualizes the investigated endpoints to
determine the value of SRS for multiple BM.
Diagnostic imaging and planning
Planning-MR, planning-CT, and registration
Based on consensus, the interval between the planning-MRI
and actual SRS treatment should be kept as short as pos-
sible. A maximum of two weeks (preferably< one week)
seems acceptable to avoid a geographical miss at the edge
of the BM due to tumor progression [30]. The planning-MR is
Gadolinium (Gd) contrast-enhanced with either single, dou-
ble, or triple dose Gd to visualize the BM. The field strength
of the MRI is in the range of 1.0T to 3T with a maximal slice
thickness of 1.5mm. MRI can have geometric distortion and
needs to be corrected, especially for the 3T MRI. Quality
assurance of the correct execution of the geometric distor-
tion correction is done at least yearly. Using independent
phantom measurements which compare cerebral CT images
without geometric distortion with the geometric distortion
corrected MRI.
A planning-CT with preferably 1mm, but 2mm thick
contiguous slices is fused to the contrast-enhanced stereo-
tactic MRI. Preferably the planning-CT is enhanced with
Iodine contrast to also visualize the BM on the planning-CT.
By default, the planning-CT is 100 kV and combined with
dose modulation (mAs) in order to achieve the optimal soft
tissue contrast. A dedicated head filtration kernel with beam
hardening correction is advised. Ideally, a small collimation is
chosen (e.g., 64 0.6mm). It is recommended that a repro-
ducible methodology is used with a well-defined protocol for
image registration of the MRI with the CT. The position of
the BM visualized on both the MRI as the CT (if visible) can
be used to check the quality of the registration. To minimize
the risk of registration errors and to identify unexpected geo-
metric distortion correction errors or artifacts of the MRI, an
independent check of the registration has to be performed
by a medical physicist and/or radiation oncologist.
Contouring and treatment planning SRS
In general, the BM are contoured based on the contrast
enhanced lesions on the planning-MR and fused with the
(contrast enhanced) planning-CT. To obtain the maximal
therapeutic ratio, e.g., tumor control probability/radionecro-
sis, while taking into consideration the geometric uncertain-
ties in the treatment chain, GTV-PTV margins are minimized
or even avoided [18,22]. Margins should ideally be based on
a CTV to PTV margin recipe taking all uncertainties into con-
sideration. However, with a sufficiently high planned pre-
scription dose and median dose to the CTV a satisfactory
dose to the CTV might still be obtained. Organs at risk are
contoured consensus based [31].
Single isocenter (non-)coplanar VMAT can be used to
maximize efficiency with maintenance of a high treatment
plan quality. This technique is a highly conformal dynamic
intensity modulated technique that delivers high doses of
radiation to the target with maximally sparing of OAR [15].
This is done by simultaneously varying the speed of the gan-
try rotation, the dose rate of the LINAC and the MLC aper-
ture shape. Compared to the conventional multiple isocenter
technique, the single isocenter VMAT approach, using one or
more gantry arcs, is characterized by a relatively short overall
treatment time [10]. For targets that are closely spaced,
including couch rotations may lead to a more conformal
result (Figures 1–2) [16,32,33]. Other planning and delivery
techniques are encouraged to achieve uniform optimized
planning quality, such as, knowledge-guided planning using
multiple non-coplanar dynamic conformal arcs or VMAT, as
well as knowledge-guided planning techniques [34,35].
The use of VMAT for SRS with flattening filter free (FFF)
photon beams has demonstrated to shorten treatment time
compared with traditional flattening filter (FF) beams [36].
FFF beams potentially have an increased dose rate which
can substantially shorten the beam-on time and result in a
more favorable dose gradient. Especially with very high sin-
gle fraction doses, reducing treatment time is an important
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issue in SRS. This improves patient comfort and might
reduce intrafraction motion. There is also some clinical
experience with FFF VMAT in elderly patients with multiple
BM. When treated with a long course radiotherapy, elderly
patients often encounter multiple barriers. Therefore, it was
concluded that LINAC-based SRS or multifraction stereotactic
radiotherapy should be taken into account as a feasible, safe
and effective treatment option for elderly patients [37].
Furthermore, a lower peripheral dose is a unique characteris-
tic in FFF beams due to the decrease of photon head scatter,
head leakage and leaf transmission [38]. It has been demon-
strated that the dose gradients in FFF beams were superior
to FF beams and that FFF provides further brain sparing
compared to traditional techniques for SRS in single brain
metastasis [39,40].
Depending on the treatment planning system used, one
will need to prescribe the dose to the PTV or isocenter. To
avoid confusion about dose prescription and reporting, it is
advised to follow the guidelines of the ICRU [41]. Dose is
prescribed depending on size of the BM varying in a single
dose of 15 up to 24Gy or 3 fractions of 8 Gy with this iso-
dose line encompassing the PTV [42]. Commonly used meth-
ods of risk adapted SRS dose prescription are shown in Table
2. To optimize the treatment planning- and delivery tech-
nique of an institution, it is advisable to compare treatment
plans with other institutions, preferably institutions that have
broad experience with LINAC based SRS. Plan quality evalu-
ation can be performed using parameters: CTV and PTV
D98% for each CTV/PTV, CTV and PTV DV-35mm3 for each
CTV/PTV, near maximum dose (D2% or D35 mm3), Median
dose D50%, Mean dose (Dmean), RTOG conformity index:
Volume (prescribed dose in treatment plan)/V(total PTVs, can
only be used if all BM are treated with equal SRS dose),
Paddick gradient index: Volume (50% of prescribed dose)/
Table 1. Measurable endpoints in trials.
Primary endpoints Difference in quality of life (EQ5D EUROQOL questionnaire) at 3 months post-
radiotherapy with respect to baseline
Neurocognitive progression-free survival
Overall survival
Secondary endpoints Karnofsky  70, WHO performance status, steroid use (mg), toxicity according
CTCAE V4.0 including hair loss, fatigue, brain salvage during follow-up, type
of salvage, time to salvage after randomization, and Barthel index, quality of
life EORTC QLQ-C30, quality of life EORTC BN20 brain module, and fatigue
scale EORTC QLQ-FA13.
Figure 1. Dose distributions of 2 SRS planning-strategies for a case with 10 brain metastases. Dose distributions are visualized on an anonymized planning-CT of a
case with 10 BM treated with 21 Gy SRS on all BM. The planes on the left show the plan made with one coplanar beam and one non-coplanar VMAT beam and
the planes on the right show the plan made with four non-coplanar VMAT beams using different couch rotations (HyperArc Varian Medical systems, right transver-
sal CT-image). The planning-CT is demonstrated in transversal (above), sagittal (below right), and coronal (below left) planes. The minimum dose which is demon-
strated is the 8 Gy color wash dose (Eclipse, Varian Medical Systems, Palo Alto, USA). With Hyperarc, steeper dose gradients are achieved and brain tissue is much
better spared than with a single non-coplanar VMAT beam.
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Volume(prescribed dose, can only be used if all BM are
treated with equal SRS dose), Maximum dose organ at risk
(D 0.035 cm3): brain stem, cochlea, chiasm, lens en optic
nerves, Total V12Gy (brain exclusive GTVs), V12 Gy largest
BM (so only the surrounding brain exclusive GTV), and the
mean brain dose. There are several publications about SRS
constraints for organ at risk that can be used to reduce the
risk of severe complications [43,44]. It is advisable to use a
volume constraint for the maximum dose in an organ at risk,
for example an acceptable variation of 0.00–0.03 cm3.
A commonly used methodology to compare treatment
plan quality between institutes, requires that every institute
make an anonymized contoured planning-CT available with a
FTP-webserver. Subsequently, every institute makes a treat-
ment plan that will then be compared among the institutes.
The above mentioned parameters are compared to evaluate
the treatment plan quality and to minimize the variation in
quality of treatment plans.
Setup, delivery, and quality assurance
There are various SRS modalities available for the treatment
of brain metastases, such as Gamma Knife, CyberKnife,
Tomotherapy and a standard linear accelerator. LINAC accel-
erators should have MLC leaves 5mm (preferably thinner)
and a 6 degree of freedom (6D) robotic couch to correct
positional and rotational errors. The patient can be accur-
ately positioned at couch 0 degrees using CBCT online
images. If a non-coplanar technique is applied, the LINAC
should also have a means of verifying patient position at dif-
ferent couch angles. This can be realized by a surface track-
ing system and/or a kV based imaging system. It is essential
that the couch rotation isocenter be kept as small as possible
as correction of errors in this sense is often impossible. One
might consider using more stringent values than the ± 1mm
as given in AAPM TG 142 [45]. Patients are immobilized in
supine position within a molded immobilization mask or
noninvasive frame-based mask, with or without bite block.
Regarding quality assurance, and in particular end-to-end
testing of a single isocenter VMAT treatment for multiple
BM, the literature is scarce [46,47]. Therefore, the goal of this
paper is attempt to formulate a minimum of QA measures
and equipment a radiation oncology center needs to set up
this state-of-the-art treatment of BM, using the information
from the different ongoing trials (Table 3).
Follow-up
Patients treated with SRS as a single modality for BM have a
relatively high risk of developing distant brain recurrences
during follow-up in the range of 50–84% [19]. Therefore
regularly follow-up MRI is justified if the patient is fit enough
to undergo salvage treatment of DBR. The optimal frequency
of follow-up MRI’s in terms of cost efficiency remains to be
determined, but a frequency of every two to three months is
commonly used [52]. Salvage treatment options for DBRs
Figure 2. Dose-Volume histograms of 2 treatment planning-strategies for SRS multiple BM: a non-coplanar VMAT beam and multiple non-coplanar beams
(HyperArc, Varian Medical Systems). Dose-volume histograms of the planning strategies in Figure 1. With 4 non-coplanar VMAT beams (triangles, HyperArc) normal
brain tissue outside the PTV is much better spared than with one one coplanar beam and one non-coplanar VMAT beam (squares). Yellow lines visualize the dose
in the brain. Red lines visualize the dose in the PTV. Treatment plans of a SRS fraction of 21 Gy, to 98% of the PTV.
Table 2. Risk adapted SRS dose prescription.
PTV of BM Dose covering PTV BM in brainstem
<1 cm3 20–24 Gy 16–20 Gy
1–4 cm3 20–24 Gy 16–18 Gy
4–10 cm3 16–20 Gy 14–16 Gy
10–20 cm3 16–18 Gy 14–16 Gy
20–65 cm3 15 Gy or 3 8Gy ¼ 24Gy No SRS
If the tolerance dose of the brain nearby the largest BM is exceeded, e.g.,
V12Gy exceeds 10 cm3, a lower prescribed dose can be used or the fraction-
ation scheme can be adapted into 3 fractions of 8 Gy to avoid the risk of
radionecrosis.
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and local failures are SRS, WBRT, neurosurgical resection in
case of a large and isolated DBR, and systemic therapy.
Conclusion
In the last decade the management of BM has seen dramatic
changes. After publication of the QUARTZ and other trials,
the indication of WBRT has become a matter of debate. SRS
is an emerging treatment option for patients with a limited
number of BM, but recently also for patients with mul-
tiple BM.
To deliver high doses to the target, with maximal sparing
of the organs at risk, single isocenter (non-)coplanar flattening
filter free VMAT is an efficient and therefore attractive delivery
technique, with comparable plan quality as Gamma- or
CyberKnife. This strategy can potentially lead to a change in
the daily practice of BM for healthcare systems making SRS
more affordable and feasible in clinical practice. It is essential
that SRS be performed with the highest achievable quality to
minimize the risk of side effects such as radionecrosis. This
paper provides guidance for quality assurance and optimiza-
tion of treatment delivery for LINAC-based radiosurgery.
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